FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076647667> ?p ?o ?g. }

• W2076647667 endingPage "911" @default.
• W2076647667 startingPage "905" @default.
• W2076647667 abstract "BACKGROUND In 2011, supported by data from two separate trauma centers, we implemented a protocol to administer tranexamic acid (TXA) in trauma patients with evidence of hyperfibrinolysis (HF) on admission. The purpose of this study was to examine whether the use of TXA in patients with HF determined by admission rapid thrombelastography was associated with improved survival. METHODS Following institutional review board approval, we evaluated all trauma patients 16 years or older admitted between September 2009 and September 2013. HF was defined as LY-30 of 3% or greater. Patients with LY-30 less than 3.0% were excluded. Patients were divided into those who received TXA (TXA group) and those who did not (no-TXA group). After univariate analyses, a purposeful, logistic regression model was developed a priori to evaluate the impact of TXA on mortality (controlling for age, sex, Injury Severity Score (ISS), arrival physiology, and base deficit). RESULTS A total of 1,032 patients met study criteria. Ninety-eight (10%) received TXA, and 934 (90%) did not. TXA patients were older (median age, 37 years vs. 32 years), were more severely injured (median ISS, 29 vs. 14), had a lower blood pressure (median systolic blood pressure 103 mm Hg vs. 125 mm Hg), and were more likely to be in shock (median, base excess, −5 mmol/dL vs. -2 mmol/dL), all p < 0.05. Twenty-three percent of the patients had a repeat thrombelastography within 6 hours; 8.8% of the TXA patients had LY-30 of 3% or greater on repeat rapid thrombelastography (vs. 10.1% in the no-TXA group, p = 0.679). Unadjusted in-hospital mortality was higher in the TXA group (40% vs. 17%, p < 0.001). There were no differences in venous thromboembolism (3.3% vs. 3.8%). Logistic regression failed to find a difference in in-hospital mortality among those receiving TXA (odds ratio, 0.74; 95% confidence interval, 0.38–1.40; p 0.80). CONCLUSION In the current study, the use of TXA was not associated with a reduction in mortality. Further studies are needed to better define who will benefit from an administration of TXA. LEVEL OF EVIDENCE Therapeutic study, level IV." @default.
• W2076647667 created "2016-06-24" @default.
• W2076647667 creator A5011352868 @default.
• W2076647667 creator A5031700185 @default.
• W2076647667 creator A5037661745 @default.
• W2076647667 creator A5042251160 @default.
• W2076647667 creator A5055279687 @default.
• W2076647667 creator A5056060130 @default.
• W2076647667 creator A5067673016 @default.
• W2076647667 creator A5090675988 @default.
• W2076647667 date "2015-05-01" @default.
• W2076647667 modified "2023-10-18" @default.
• W2076647667 title "The impact of tranexamic acid on mortality in injured patients with hyperfibrinolysis" @default.
• W2076647667 cites W1992034786 @default.
• W2076647667 cites W2012191523 @default.
• W2076647667 cites W2033971296 @default.
• W2076647667 cites W2038717349 @default.
• W2076647667 cites W2048928322 @default.
• W2076647667 cites W2078658631 @default.
• W2076647667 cites W2083139851 @default.
• W2076647667 cites W2087792760 @default.
• W2076647667 cites W2105453284 @default.
• W2076647667 doi "https://doi.org/10.1097/ta.0000000000000612" @default.
• W2076647667 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25909408" @default.
• W2076647667 hasPublicationYear "2015" @default.
• W2076647667 type Work @default.
• W2076647667 sameAs 2076647667 @default.
• W2076647667 citedByCount "87" @default.
• W2076647667 countsByYear W20766476672015 @default.
• W2076647667 countsByYear W20766476672016 @default.
• W2076647667 countsByYear W20766476672017 @default.
• W2076647667 countsByYear W20766476672018 @default.
• W2076647667 countsByYear W20766476672019 @default.
• W2076647667 countsByYear W20766476672020 @default.
• W2076647667 countsByYear W20766476672021 @default.
• W2076647667 countsByYear W20766476672022 @default.
• W2076647667 countsByYear W20766476672023 @default.
• W2076647667 crossrefType "journal-article" @default.
• W2076647667 hasAuthorship W2076647667A5011352868 @default.
• W2076647667 hasAuthorship W2076647667A5031700185 @default.
• W2076647667 hasAuthorship W2076647667A5037661745 @default.
• W2076647667 hasAuthorship W2076647667A5042251160 @default.
• W2076647667 hasAuthorship W2076647667A5055279687 @default.
• W2076647667 hasAuthorship W2076647667A5056060130 @default.
• W2076647667 hasAuthorship W2076647667A5067673016 @default.
• W2076647667 hasAuthorship W2076647667A5090675988 @default.
• W2076647667 hasConcept C126322002 @default.
• W2076647667 hasConcept C141071460 @default.
• W2076647667 hasConcept C144301174 @default.
• W2076647667 hasConcept C151956035 @default.
• W2076647667 hasConcept C190385971 @default.
• W2076647667 hasConcept C194828623 @default.
• W2076647667 hasConcept C2776825266 @default.
• W2076647667 hasConcept C2779637338 @default.
• W2076647667 hasConcept C2781219028 @default.
• W2076647667 hasConcept C2910686401 @default.
• W2076647667 hasConcept C2991743468 @default.
• W2076647667 hasConcept C3017944768 @default.
• W2076647667 hasConcept C38180746 @default.
• W2076647667 hasConcept C42219234 @default.
• W2076647667 hasConcept C71924100 @default.
• W2076647667 hasConcept C84393581 @default.
• W2076647667 hasConcept C85004164 @default.
• W2076647667 hasConcept C89560881 @default.
• W2076647667 hasConceptScore W2076647667C126322002 @default.
• W2076647667 hasConceptScore W2076647667C141071460 @default.
• W2076647667 hasConceptScore W2076647667C144301174 @default.
• W2076647667 hasConceptScore W2076647667C151956035 @default.
• W2076647667 hasConceptScore W2076647667C190385971 @default.
• W2076647667 hasConceptScore W2076647667C194828623 @default.
• W2076647667 hasConceptScore W2076647667C2776825266 @default.
• W2076647667 hasConceptScore W2076647667C2779637338 @default.
• W2076647667 hasConceptScore W2076647667C2781219028 @default.
• W2076647667 hasConceptScore W2076647667C2910686401 @default.
• W2076647667 hasConceptScore W2076647667C2991743468 @default.
• W2076647667 hasConceptScore W2076647667C3017944768 @default.
• W2076647667 hasConceptScore W2076647667C38180746 @default.
• W2076647667 hasConceptScore W2076647667C42219234 @default.
• W2076647667 hasConceptScore W2076647667C71924100 @default.
• W2076647667 hasConceptScore W2076647667C84393581 @default.
• W2076647667 hasConceptScore W2076647667C85004164 @default.
• W2076647667 hasConceptScore W2076647667C89560881 @default.
• W2076647667 hasIssue "5" @default.
• W2076647667 hasLocation W20766476671 @default.
• W2076647667 hasLocation W20766476672 @default.
• W2076647667 hasOpenAccess W2076647667 @default.
• W2076647667 hasPrimaryLocation W20766476671 @default.
• W2076647667 hasRelatedWork W2048405032 @default.
• W2076647667 hasRelatedWork W2054656237 @default.
• W2076647667 hasRelatedWork W2087194039 @default.
• W2076647667 hasRelatedWork W2289205756 @default.
• W2076647667 hasRelatedWork W2410239919 @default.
• W2076647667 hasRelatedWork W2908008303 @default.
• W2076647667 hasRelatedWork W2932080593 @default.
• W2076647667 hasRelatedWork W3005553386 @default.
• W2076647667 hasRelatedWork W3086002268 @default.
• W2076647667 hasRelatedWork W3202835104 @default.
• W2076647667 hasVolume "78" @default.

• next